Viropharma Inc - VPHM - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Viropharma Inc - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
VPHM	Nasdaq	8731	http://www.viropharma.com	25.86 +0.56
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Viropharma Inc Halozyme rises on pancreatic cancer drug study - May 16th, 2013 2:41 pm Halozyme rises on pancreatic cancer drug study - May 16th, 2013 2:41 pm Halozyme rises on prostate cancer drug study - May 16th, 2013 2:15 pm Halozyme rises on prostate cancer drug study - May 16th, 2013 2:15 pm ViroPharma Proudly Supports HAE Day :-) 2013 - May 15th, 2013 11:00 pm Viropharma's CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) - May 14th, 2013 10:22 pm ViroPharma (VPHM) Shares Cross Above 200 DMA - May 13th, 2013 10:17 am ViroPharma To Participate In Two May Healthcare Investor Conferences - May 9th, 2013 3:00 pm VIROPHARMA INC Financials - May 7th, 2013 11:04 am Biota Pharmaceuticals Announces Changes to Its Board of Directors - May 6th, 2013 5:00 am Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continue - May 3rd, 2013 7:10 pm ViroPharma Reports Loss in 1Q - May 2nd, 2013 11:30 am The Zacks Analyst Blog Highlights: AT&T, Optimer Pharmaceuticals, ViroPharma, Astellas Pharma and Incyte - May 2nd, 2013 6:20 am Optimer's Dificid Cleared Down Under - May 1st, 2013 3:00 pm ViroPharma Management Discusses Q1 2013 Results - Earnings Call Transcript - May 1st, 2013 1:20 pm ViroPharma's Maribavir: Rising Like Phoenix - May 1st, 2013 11:02 am Positive News in the Oncology Space Regarding Myeloma and Melanoma Drugs: Expert Analyst Boris Peaker Discusses Recent Successes for Biotechnology Companies - May 1st, 2013 9:15 am ViroPharma Earnings: Here’s Why the Stock is Down Now - May 1st, 2013 7:49 am ViroPharma Announces First Quarter 2013 Financial Results - May 1st, 2013 5:30 am Q1 2013 ViroPharma Earnings Release - Before Market Open - May 1st, 2013 5:07 am View All Current Headlines >>